Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE

Atherosclerosis plus Pub Date : 2024-02-17 DOI:10.1016/j.athplu.2024.01.004

Katsiki N , Filippatos Td , Vlachopoulos C , Panagiotakos D , Milionis H , Tselepis A , Garoufi A , Rallidis L , Richter D , Nomikos T , Kolovou G , Kypreos K , Chrysohoou C , Tziomalos K , Skoumas I , Koutagiar I , Attilakos A , Papagianni M , Boutari C , Kotsis V , Liberopoulos E

{"title":"Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023","authors":"Katsiki N , Filippatos Td , Vlachopoulos C , Panagiotakos D , Milionis H , Tselepis A , Garoufi A , Rallidis L , Richter D , Nomikos T , Kolovou G , Kypreos K , Chrysohoou C , Tziomalos K , Skoumas I , Koutagiar I , Attilakos A , Papagianni M , Boutari C , Kotsis V , Liberopoulos E","doi":"10.1016/j.athplu.2024.01.004","DOIUrl":null,"url":null,"abstract":"<div><p>Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"55 ","pages":"Pages 74-92"},"PeriodicalIF":1.4000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266708952400004X/pdfft?md5=9461b24442f342030f6ea703f518b6fb&pid=1-s2.0-S266708952400004X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266708952400004X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.

查看原文本刊更多论文

希腊动脉粥样硬化学会血脂异常诊断和治疗指南执行摘要 - 2023 年

动脉粥样硬化性心血管疾病（ASCVD）仍然是全球的主要死因，因此其预防、早期诊断和治疗至关重要。血脂异常是动脉粥样硬化性心血管疾病的一个主要风险因素，应在不同的临床环境中加以适当管理。希腊动脉粥样硬化学会 2023 年指南重点关注 ASCVD 风险评估、血脂异常的实验室评估、新出现的降脂药物，以及女性、老年人和家族性高胆固醇血症、急性冠状动脉综合征、心力衰竭、中风、慢性肾病、糖尿病、自身免疫性疾病和非酒精性脂肪肝患者的血脂紊乱诊断和治疗。此外，还讨论了他汀类药物不耐受的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Atherosclerosis plus Cardiology and Cardiovascular Medicine

CiteScore

2.60

自引率

0.00%

发文量

审稿时长

66 days